SCHEMBL5652827

SCHEMBL5652827

NCCCNC(=O)c1ccc(-c2nc3cc(C(F)(F)F)cc(Cl)c3[nH]2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 9/20 0.51
P2RY14 Q15391 2/20 0.43
OPRD1 P41143 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
PRSS12 P56730 1/20 0.42
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
MAPK8 P45983 1/20 0.41
SCD O00767 1/20 0.41
RHOC P08134 1/20 0.41
RHOA P61586 1/20 0.41
CHEK2 O96017 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650773 0.88 FLT3 (0.49) FLT3RHOCRHOAMRGPRX4LMNA
SCHEMBL5651712 0.86 FLT3 (0.48) FLT3P2RY14RHOCRHOAMRGPRX4
SCHEMBL5651383 0.86 FLT3 (0.48) FLT3RHOCRHOAMRGPRX4
SCHEMBL5647982 0.86 HDAC6 (0.50) SIGMAR1PRSS12GSK3AGSK3BLMNA
SCHEMBL5652819 0.85 FLT3 (0.54) FLT3P2RY14OPRD1SIGMAR1PRSS12
SCHEMBL5649045 0.84 FLT3 (0.46) FLT3MRGPRX4MAPT
SCHEMBL5653307 0.84 FLT3 (0.64) FLT3P2RY14OPRD1SIGMAR1MAPK8
SCHEMBL5651235 0.83 CD274 (0.55)
SCHEMBL5650717 0.83 FLT3 (0.45) FLT3RHOCRHOAMRGPRX4
SCHEMBL5653300 0.82 FLT3 (0.72) FLT3CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 FLT3 1968/4885P2RY14 3176/4885OPRD1 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.